Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 Apr 4;162(7):977–983.

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model

S A Grover 1, L Coupal 1, H Zowall 1, R Rajan 1, J Trachtenberg 1, M Elhilali 1, M Chetner 1, L Goldenberg 1
PMCID: PMC1232349  PMID: 10763395

Abstract

OBJECTIVES: The incidence of prostate cancer is increasing, as is the number of diagnostic and therapeutic interventions to manage this disease. We developed a Markov state-transition model--the Montreal Prostate Cancer Model--for improved forecasting of the health care requirements and outcomes associated with prostate cancer. We then validated the model by comparing its forecasted outcomes with published observations for various cohorts of men. METHODS: We combined aggregate data on the age-specific incidence of prostate cancer, the distribution of diagnosed tumours according to patient age, clinical stage and tumour grade, initial treatment, treatment complications, and progression rates to metastatic disease and death. Five treatments were considered: prostatectomy, radiation therapy, hormonal therapies, combination therapies and watchful waiting. The resulting model was used to calculate age-, stage-, grade- and treatment-specific clinical outcomes such as expected age at prostate cancer diagnosis and death, and metastasis-free, disease-specific and overall survival. RESULTS: We compared the model's forecasts with available cohort data from the Surveillance, Epidemiology and End Results (SEER) Program, based on over 59,000 cases of localized prostate cancer. Among the SEER cases, the 10-year disease-specific survival rates following prostatectomy for tumour grades 1, 2 and 3 were 98%, 91% and 76% respectively, as compared with the model's estimates of 96%, 92% and 84%. We also compared the model's forecasts with the grade-specific survival among patients from the Connecticut Tumor Registry (CTR). The 10-year disease-specific survival among the CTR cases for grades 1, 2 and 3 were 91%, 76% and 54%, as compared with the model's estimates of 91%, 73% and 37%. INTERPRETATION: The Montreal Prostate Cancer Model can be used to support health policy decision-making for the management of prostate cancer. The model can also be used to forecast clinical outcomes for individual men who have prostate cancer or are at risk of the disease.

Full Text

The Full Text of this article is available as a PDF (242.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albertsen P. C., Fryback D. G., Storer B. E., Kolon T. F., Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995 Aug 23;274(8):626–631. [PubMed] [Google Scholar]
  2. Barry M. J., Fleming C., Coley C. M., Wasson J. H., Fahs M. C., Oesterling J. E. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology. 1995 Sep;46(3):277–289. doi: 10.1016/S0090-4295(99)80208-8. [DOI] [PubMed] [Google Scholar]
  3. Beck J. R., Pauker S. G. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419–458. doi: 10.1177/0272989X8300300403. [DOI] [PubMed] [Google Scholar]
  4. Chamberlain J., Melia J., Moss S., Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol. 1997 May;79 (Suppl 3):1–32. doi: 10.1111/j.1464-410x.1997.tb16914.x. [DOI] [PubMed] [Google Scholar]
  5. Chodak G. W., Thisted R. A., Gerber G. S., Johansson J. E., Adolfsson J., Jones G. W., Chisholm G. D., Moskovitz B., Livne P. M., Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. doi: 10.1056/NEJM199401273300403. [DOI] [PubMed] [Google Scholar]
  6. Coley C. M., Barry M. J., Fleming C., Mulley A. G. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med. 1997 Mar 1;126(5):394–406. doi: 10.7326/0003-4819-126-5-199703010-00010. [DOI] [PubMed] [Google Scholar]
  7. Cowen M. E., Chartrand M., Weitzel W. F. A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994 Jan;47(1):3–21. doi: 10.1016/0895-4356(94)90029-9. [DOI] [PubMed] [Google Scholar]
  8. Fleming C., Wasson J. H., Albertsen P. C., Barry M. J., Wennberg J. E. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2650–2658. [PubMed] [Google Scholar]
  9. Fowler F. J., Jr, Barry M. J., Lu-Yao G., Roman A., Wasson J., Wennberg J. E. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993 Dec;42(6):622–629. doi: 10.1016/0090-4295(93)90524-e. [DOI] [PubMed] [Google Scholar]
  10. Fowler F. J., Jr, Barry M. J., Lu-Yao G., Wasson J. H., Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol. 1996 Aug;14(8):2258–2265. doi: 10.1200/JCO.1996.14.8.2258. [DOI] [PubMed] [Google Scholar]
  11. Gerber G. S., Thisted R. A., Scardino P. T., Frohmuller H. G., Schroeder F. H., Paulson D. F., Middleton A. W., Jr, Rukstalis D. B., Smith J. A., Jr, Schellhammer P. F. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996 Aug 28;276(8):615–619. [PubMed] [Google Scholar]
  12. Grover S. A., Coupal L., Zowall H., Rajan R., Trachtenberg J., Elhilali M., Chetner M., Goldenberg L. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000 Apr 4;162(7):987–992. [PMC free article] [PubMed] [Google Scholar]
  13. Grover S. A., Zowall H., Coupal L., Krahn M. D. Prostate cancer: 12. The economic burden. CMAJ. 1999 Mar 9;160(5):685–690. [PMC free article] [PubMed] [Google Scholar]
  14. Johansson J. E., Holmberg L., Johansson S., Bergström R., Adami H. O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997 Feb 12;277(6):467–471. [PubMed] [Google Scholar]
  15. Krahn M. D., Mahoney J. E., Eckman M. H., Trachtenberg J., Pauker S. G., Detsky A. S. Screening for prostate cancer. A decision analytic view. JAMA. 1994 Sep 14;272(10):773–780. [PubMed] [Google Scholar]
  16. Lawton C. A., Won M., Pilepich M. V., Asbell S. O., Shipley W. U., Hanks G. E., Cox J. D., Perez C. A., Sause W. T., Doggett S. R. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935–939. doi: 10.1016/0360-3016(91)90732-j. [DOI] [PubMed] [Google Scholar]
  17. Lee R. J., Sause W. T. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results. Urology. 1994 May;43(5):640–644. doi: 10.1016/0090-4295(94)90178-3. [DOI] [PubMed] [Google Scholar]
  18. Lu-Yao G. L., McLerran D., Wasson J., Wennberg J. E. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2633–2636. doi: 10.1001/jama.269.20.2633. [DOI] [PubMed] [Google Scholar]
  19. Lu-Yao G. L., Potosky A. L., Albertsen P. C., Wasson J. H., Barry M. J., Wennberg J. E. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996 Feb 21;88(3-4):166–173. doi: 10.1093/jnci/88.3-4.166. [DOI] [PubMed] [Google Scholar]
  20. Lu-Yao G. L., Yao S. L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997 Mar 29;349(9056):906–910. doi: 10.1016/S0140-6736(96)09380-4. [DOI] [PubMed] [Google Scholar]
  21. Lubke W. L., Optenberg S. A., Thompson I. M. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst. 1994 Dec 7;86(23):1790–1792. doi: 10.1093/jnci/86.23.1790. [DOI] [PubMed] [Google Scholar]
  22. Mellinger G. T., Gleason D., Bailar J., 3rd The histology and prognosis of prostatic cancer. J Urol. 1967 Feb;97(2):331–337. doi: 10.1016/S0022-5347(17)63039-8. [DOI] [PubMed] [Google Scholar]
  23. Mettlin C. J., Murphy G. P., Ho R., Menck H. R. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996 May 15;77(10):2162–2166. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2162::AID-CNCR30>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  24. Mettlin C. J., Murphy G. P., McGinnis L. S., Menck H. R. The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995 Sep 15;76(6):1104–1112. doi: 10.1002/1097-0142(19950915)76:6<1104::aid-cncr2820760627>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  25. Mettlin C. J., Murphy G. The National Cancer Data Base report on prostate cancer. Cancer. 1994 Sep 1;74(5):1640–1648. doi: 10.1002/1097-0142(19940901)74:5<1640::aid-cncr2820740525>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  26. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  27. Perez C. A., Pilepich M. V., Garcia D., Simpson J. R., Zivnuska F., Hederman M. A. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. NCI Monogr. 1988;(7):85–94. [PubMed] [Google Scholar]
  28. Potosky A. L., Miller B. A., Albertsen P. C., Kramer B. S. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995 Feb 15;273(7):548–552. [PubMed] [Google Scholar]
  29. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322–338. doi: 10.1177/0272989X9301300409. [DOI] [PubMed] [Google Scholar]
  30. Wasson J. H., Cushman C. C., Bruskewitz R. C., Littenberg B., Mulley A. G., Jr, Wennberg J. E. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. doi: 10.1001/archfami.2.5.487. [DOI] [PubMed] [Google Scholar]
  31. Zagars G. K., von Eschenbach A. C., Johnson D. E., Oswald M. J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987 Oct 1;60(7):1489–1499. doi: 10.1002/1097-0142(19871001)60:7<1489::aid-cncr2820600715>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  32. Zincke H. Re: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1994 Feb;151(2):435–435. doi: 10.1016/s0022-5347(17)34978-9. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES